Novalar Pharmaceuticals has entered into an agreement with HA Systems Dental Imports, an Israel-based company, to distribute OraVerse in Israel and the Palestinian Territories.
As per the terms of the agreement, HA Systems will file the necessary documentation for regulatory approval of OraVerse with the Israel Ministry of Health. Upon approval, HA Systems will have exclusive rights to promote and distribute OraVerse to dentists in the territory through the company’s established dental franchise and sales force.
Novalar Pharma claimed that OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the US by the FDA and sold by Novalar direct to dentists in the US.
Donna Janson, president and CEO of Novalar, said: “This collaboration is yet another important step in expanding Novalar’s international commercialisation efforts. As Israel offers patients exceptional dental care, this market is extremely attractive for us.”
Fanny Gross, president and CEO of HA Systems, said: “HA Systems has significant experience launching new and innovative dental products and providing continuing education and scientific support to the profession.
“We also have the necessary infrastructure and existing relationships within the local dental community for the successful launch of OraVerse in Israel and we look forward to offering this unique product to our customers.”